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The main missions of the university are the production
and dissemination of knowledge, with education and
research serving as the fundamental pillars of these
missions. The extent of the university’s role is reflected in
its social commitment to the community. However, in
medicine, this ‘‘extended’’ role involves promoting health
care for citizens. In general, all academic institutions and
their faculty are evaluated externally according to their
performance of these criteria. Therefore, a university
professor of medicine in the Brazilian model must teach,
conduct research and also treat patients.
In recent years, Brazilian national scientific policy (which
is determined by the Ministry of Education through the
Coordination for the Improvement of Higher Education
Personnel [CAPES], the governmental agency that evaluates
and regulates postgraduate programs) has begun requiring
a high level of research performance from university
teachers, with the aim of improving the quality of national
scientific production and with a particular focus on
innovation.
In most developed countries, medical practice and
medical scientific research are supervised by regulatory
agencies. The primary purpose of these agencies is to
protect and preserve the rights and interests of the
population, thereby untethering them from those of
industry and the scientific community. For example, in the
United States, the FDA (U.S. Food and Drug
Administration) is responsible for protecting public health
by ensuring the safety and efficacy of drugs, biological
products and medical devices, as well as food, cosmetics
and tobacco products. As a science-based regulatory agency,
the mission of the FDA is to promote excellence, protect
health, prevent disease, prolong life and promote the
welfare of American citizens. Therefore, studies performed
to gain FDA approval of drugs, devices and their associated
medical treatments must obey strict scientific standards,
which greatly increase the cost and time required to gain
final approval. In Europe, the ‘CE Marking’ (from French
Conformite´ Europe´ene) acts in a similar capacity to the
FDA, deciding whether a product complies with the
essential requirements of European health legislation and
with safety and environmental protection policies.
In Brazil, these practices are also regulated by strict
governmental and civilian agencies. However, both the
difficulties inherent in bureaucracy and the complexity of
the requirements limit the progress of research, as this
complexity is ultimately responsible for considerable diffi-
culties.
Created in 1999, the National Health Surveillance Agency
(ANVISA) is an autarchy that covers all aspects related to
the regulation of products and services that affect the health
of the population. Similar to the American FDA and the
European CE Marking, the function of ANVISA is to protect
public health and to intervene in hazardous production and
the use of services and products being subjected to sanitary
surveillance. However, there is no proper communication or
information exchange between ANVISA and international
regulatory agencies. The lack of this type of collaboration
can incur a large waste of national resources during the
approval of drugs or medical materials that have already
been extensively tested outside Brazil.
The National Committee for Ethics in Research (CONEP)
was created in 1996 as a collegiate body, with advisory,
educational and policy and strategy formulation roles
within the National Health Council and independence from
corporate and institutional influences. It also has a multi-
and transdisciplinary composition and includes representa-
tive members of the community.
CONEP’s task is to examine the ethical aspects of research
involving humans. Its mission consists of establishing and
updating the guidelines and standards for the protection of
research subjects and coordinating the network of research
ethics committees of the institutions at which research is
performed. CONEP evaluates and monitors the following
areas: research protocols in special fields, such as genetics
and human reproduction; new equipment; health devices;
new procedures; indigenous populations; projects involving
biosafety; and projects with foreign participation. CONEP
also forms the board of appeals for issues falling within
above-mentioned areas.
Although the roles of the various regulatory agencies are
well defined and always aimed at protecting society, in
practice, interagency interactions can be improved to
increase access to them and facilitate clinical research
without compromising their main function of ensuring the
safety and quality of medical products used in Brazil.
A device or medication that has not been approved by
ANVISA may not be imported unless a clinical study of
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the item has been approved by CONEP. CONEP is the
government agency that controls research in Brazil, and it
has the autonomy to allow the importation of consumables
and equipment for scientific research purposes without
registration through ANVISA.
However, researchers communicate with the research ethics
committees (CEPs) of their respective institutions, but the
CEPs do not communicate with CONEP or ANVISA.
Therefore, researchers are also responsible for submitting their
projects to CONEP, which increases paperwork and makes it
even more difficult to conduct national clinical studies.
Another problem is that ANVISA and CONEP often fail
to interact with each other, creating the need for researchers
to engage in dialogues with both agencies. This situation is
even more dramatic when we consider that the evaluation
metrics and bureaucratic procedures/requirements are
not uniform across agencies, forcing the researcher to be
"multilingual" and to learn how to engage in "dialogues"
with all the agencies, which requires dedicating time and
effort toward a task that is outside his/her area of expertise.
After securing approval for a clinical trial protocol,
logistical difficulties remain because the organizations for
research funding (state foundations that support research,
such as FINEP and CNPq) each require their own set of
procedures that are independent of each other.
In Brazil, medical researchers are generally also actuat-
ing physicians (care function) and teachers (teaching
function); they therefore find it difficult to pay attention
to the research approval process while providing the
required dedication to the development and execution of
projects. As a result, research groups are often forced to
hire other professionals to perform bureaucratic functions,
making clinical trials more costly and time consuming and
sometimes even unfeasible, particularly for smaller teams.
These conditions may help explain the low level of
resources made available for research and development
through the investments of global pharmaceutical compa-
nies in Brazil.
We highlight the need a better interface between ANVISA
and international entities and between CEPs and govern-
mental agencies. These improvements would allow
researchers to limit their interactions to the CEP of their
institution, which would optimize efforts and speed up and
reduce the costs of clinical trials in Brazil. Consequently, the
whole society would ‘‘profit’’’ from the increase in national
scientific production.
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